Biotech Values

[mcbio]

1. NKTR118, at least now we know why AZN delayed 118 for so long. They have been opimizing dosing for phase III. Phase III dosage are 12.5mg, 25mg while phase II dosage were 5mg, 25mg, 50mg, 100mg.

Do you see the potential for NKTR118 being a sufficient overhang for PGNX for some time? The PR says filing for 118 isn't expected until 2013 (assuming positive results of course) so I'm assuming there won't be any Phase 3 results until at least mid-2012. Hopefully PGNX will have a decision on an expanded label for subQ Relistor and Phase 3 results on oral Relistor by this time. If positive, hopefully both events would outweigh any potential concerns over NKTR's 118 and push PGNX shares higher.